Difference between revisions of "Niraparib and abiraterone (Akeega)"
Jump to navigation
Jump to search
m (→Also known as) |
m |
||
Line 16: | Line 16: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:Mutation-specific medications]] | [[Category:Mutation-specific medications]] | ||
− | [[Category: | + | [[Category:PARP1 inhibitors]] |
+ | [[Category:PARP2 inhibitors]] | ||
[[Category:CYP17 inhibitors]] | [[Category:CYP17 inhibitors]] | ||
Revision as of 18:16, 19 November 2023
Mechanism of action
A fixed dose combination of niraparib and abiraterone. Niraparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes PARP-1 and PARP-2, which are involved in DNA repair. Inhibiting PARP-1 and PARP-2 may result in formation of PARP-DNA complexes, DNA damage, apoptosis, and cell death. PARP proteins utilize base-excision repair (BER) to identify and repair single strand DNA breaks. Abiraterone is an antiandrogen, androgen biosynthesis inhibitor, CYP17 inhibitor. Inhibits the 17 α-hydroxylase/C17,20-lyase (CYP17) enzyme that is required for androgen biosynthesis, leading to a decrease in androgen production in testicular, adrenal, and prostate tumor tissues.
Diseases for which it is established
History of changes in FDA indication
- 2023-08-11: Initial approval with prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved test. (Based on MAGNITUDE)
History of changes in EMA indication
- 2023-04-19: Initial authorisation for treatment of adult patients with prostate cancer.
Also known as
- Code name: CJNJ-67652000
- Brand name: Akeega